Apptronik, a Texas-based robotics company, announced on Thursday that it has raised $350 million in a funding round led by B Capital and Capital Factory, with participation from Alphabet’s Google. The funds
Reddit Inc.’s impressive rise since going public last year has sparked investor optimism, especially as the social media platform prepares to release its earnings on Wednesday. Investors will be closely watching Reddit’s
Alibaba Group Holding Ltd. is once again a favourite among investors, driven by renewed optimism surrounding its role in China’s burgeoning artificial intelligence (AI) market. The e-commerce giant’s Hong Kong-listed shares have
Jason Eichenholz’s journey demonstrates how founders, after achieving success and retiring, can be drawn back into action when a new opportunity sparks their passion. Eichenholz co-founded Luminar Technologies, the company behind self-driving
Nissan Motor is considering forging new partnerships, including potential collaborations with technology companies, following the breakdown of merger talks with cross-town rival Honda Motor. The two companies had been in discussions to
Tokyo Electron Ltd. has reaffirmed its annual outlook and revealed plans to build a new ¥104 billion ($681 million) plant, signalling the company’s expectation for sustained artificial intelligence (AI) spending. The announcement
Honda Motor’s U.S.-listed shares surged nearly 6% in premarket trading following reports that the Japanese automaker’s proposed merger with Nissan is at risk due to a last-minute structural change introduced by Honda.
Samsung Electronics has received approval to supply its high-bandwidth memory (HBM) chips to Nvidia, marking a crucial step in its effort to close the gap with SK Hynix, the leading supplier of
Microsoft CEO Satya Nadella remains unshaken by the recent surge in attention surrounding Chinese AI startup DeepSeek, asserting that the AI landscape is following a familiar trajectory of technological evolution and cost
Roche has set its sights on high single-digit growth in adjusted earnings per share (EPS) for 2025, attributing its optimistic outlook to cost reductions and strong sales from key drugs, including the
